Licensing Out Platform Technology

Licensing Out Platform Technology

Chiome Bioscience licenses the ADLib® system.

A technology transfer of the highly standardized ADLib® system can be accomplished in a short period of time under the guidance of our research personnel. Our clients can then manufacture their own antibodies.

Advantages for our Clients

  • With unparalleled speed and the ability to deal with difficult antigens, the ADLib® system is a powerful weapon in the arsenal of antibody research teams not satisfied with the performance of conventional techniques.
  • Once installed in a client’s facility, the ADLib® system can be expanded to meet the client’s needs for therapeutic antibody research.

R&D Flow

Chiome Bioscience Inc. provides a service in which we license the ADLib® system to clients and the clients can then shoulder their own risks when generating antibodies.